Affiliations
- 1 From the Department of Renal Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia.A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke's Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke's Hospital; Y.W. Chow, MD(USM), MRCP( UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke's Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke's Hospital. aladdin.mohammad@med.lu.se
- 2 From the Department of Renal Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia.A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke's Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke's Hospital; Y.W. Chow, MD(USM), MRCP( UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke's Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke's Hospital
PMID: 26276966
DOI: 10.3899/jrheum.141344
Abstract
To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.